Adam Maeder
Stock Analyst at Piper Sandler
(3.19)
# 1,055
Out of 5,143 analysts
109
Total ratings
44%
Success rate
3.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $28.65 | +46.60% | 6 | Feb 18, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $165 → $85 | $57.72 | +47.26% | 18 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $82.40 | +21.36% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $251.63 | +9.29% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $494.02 | +25.50% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $114.58 | +17.82% | 4 | Jan 23, 2026 | |
| RXST RxSight | Maintains: Neutral | $10 → $11 | $8.94 | +23.04% | 3 | Jan 20, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $5.25 | +71.43% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $4.27 | +110.72% | 9 | Nov 14, 2025 | |
| RBOT Vicarious Surgical | Maintains: Neutral | $8.5 → $7 | $2.01 | +248.26% | 8 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4.5 → $4 | $1.85 | +116.22% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $20.83 | +0.82% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.27 | +529.92% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.10 | +138.10% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $69.05 | +43.37% | 3 | May 5, 2022 |
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $28.65
Upside: +46.60%
Inspire Medical Systems
Feb 12, 2026
Maintains: Overweight
Price Target: $165 → $85
Current: $57.72
Upside: +47.26%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $82.40
Upside: +21.36%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $251.63
Upside: +9.29%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $494.02
Upside: +25.50%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $114.58
Upside: +17.82%
RxSight
Jan 20, 2026
Maintains: Neutral
Price Target: $10 → $11
Current: $8.94
Upside: +23.04%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $5.25
Upside: +71.43%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $4.27
Upside: +110.72%
Vicarious Surgical
Aug 13, 2025
Maintains: Neutral
Price Target: $8.5 → $7
Current: $2.01
Upside: +248.26%
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.85
Upside: +116.22%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $20.83
Upside: +0.82%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.27
Upside: +529.92%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.10
Upside: +138.10%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $69.05
Upside: +43.37%